Get the Stockscreener App
1.15
0.87%
0.0099
After Hours:
1.15
Cardiol Therapeutics Inc stock is traded at $1.15, with a volume of 85,206.
It is up +0.87% in the last 24 hours and up +25.68% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.1401
Open:
$1.13
24h Volume:
85,206
Relative Volume:
0.39
Market Cap:
$94.20M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.4628
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+0.88%
1M Performance:
+25.68%
6M Performance:
-42.21%
1Y Performance:
-47.96%
1-Day Range:
$1.11
$1.1569
1-Week Range:
$1.05
$1.1696
52-Week Range:
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.15 | 94.20M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
(CRDL) Advanced Trading Insights (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of “Buy” by Analysts - Defense World
Envestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
(CRDL) Market Insights and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
Lodgement of CONNEQT Pulse Device with the TGA - Investing News Network
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Daily Stock Insights (CRDL:CA) - news.stocktradersdaily.com
March Quarterly Activities Report - Investing News Network
March Quarterly Appendix 4C - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% – What’s Next? - Defense World
Profound Medical Corp. - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors | CRDL Stock News - GuruFocus
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress - TipRanks
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile
Cardiol Therapeutics Taps 30-Year Pharma Veteran and Ex-Eli Lilly CMO to Strengthen Clinical Strategy - Stock Titan
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com India
Cardiol Therapeutics announces annual shareholder meeting - Investing.com
Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025 - TipRanks
First patient dosed in Phase IIb imaging for Brain Mets - Investing News Network
(CRDL) Strategic Market Analysis (CRDL:CA) - news.stocktradersdaily.com
A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David ElsleyCardiol Therapeutics - thedeepdive.ca
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? - Nasdaq
Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review - Defense World
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Northwestern University enrols first subject in trial of drug for pericarditis - Yahoo
(CRDL) Pivots Trading Plans and Risk Controls (CRDL:CA) - news.stocktradersdaily.com
ardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Commences Phase III Trial for CardiolRx™ in Recurrent Pericarditis - TipRanks
Cardiol Therapeutics starts phase III trial for heart drug - Investing.com Australia
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile
3 Reasons to Sell CSV and 1 Stock to Buy Instead - The Globe and Mail
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses - TipRanks
HC Wainwright Has Negative Outlook for CRDL FY2025 Earnings - Defense World
H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock By Investing.com - Investing.com UK
Cardiol Therapeutics (NASDAQ:CRDL) Receives “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell? - Defense World
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Yahoo Finance
Cardiol Therapeutics advances heart disease treatments By Investing.com - Investing.com South Africa
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results - TipRanks
Cardiol Therapeutics advances heart disease treatments - Investing.com
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):